Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod

시포니모드로 치료받은 이차 진행성 다발성 경화증 환자의 COVID-19 백신에 대한 체액 면역 반응

Published on
Journal: Multiple sclerosis and related disorders
[저자] Magdalena Krbot Skorić, Dunja Rogić, Ivana Lapić, Dragana Šegulja, Mario Habek
[Category] MERS, SARS, 진단,
PMC URL    [DOI] 10.1016/j.msard.2021.103435    
[Article Type] Article
[Source] PMC

Abstract
Objective: The aim of this study is to determine a development of humoral response after COVID-19 vaccination in persons with secondary progressive multiple sclerosis (pwSPMS) on siponimod, compared to healthy controls (HC).
Methods: In 13 pwSPMS taking siponimod and 11 HC, testing for SARS-CoV2 antibodies was performed after vaccination against COVID-19.
Results: pwSPMS taking siponimod had a significantly lower titer of SARS-CoV2 antibodies compared to healthy controls (19.4 (0-250) vs. 250 (250), p>0.001). Two (15.4%) pwSPMS on siponimod had unmeasurable titers of SARS-CoV2-2 antibodies, while all HC had positive titers.
Conclusion: Although the results of this study are limited by a small sample size, results have consistently shown low titers of SARS-CoV-2 IgG after COVID-19 vaccinations in pwSPMS on siponimod.
Keywords: COVID-19; SARS-CoV-2 IgG antibody; Secondary progressive multiple sclerosis; Siponimod; Vaccines.

All Keywords
【저자키워드】 COVID-19, Vaccines, SARS-CoV-2 IgG antibody, Secondary progressive multiple sclerosis, Siponimod, 【초록키워드】 antibodies, SARS-CoV2, multiple sclerosis, antibody, COVID-19 vaccination, SARS-CoV-2 IgG, humoral, healthy control, small sample size, positive, significantly lower, vaccination against COVID-19, secondary, shown, was performed, determine, 【제목키워드】 COVID-19 vaccine, immune response, multiple sclerosis, Siponimod, treated,
{{{ 추상적인 }}} {{ 목적: }} 이 연구의 목적은 건강한 대조군(HC)과 비교하여 시포니모드에 대한 이차 진행성 다발성 경화증(pwSPMS) 환자에서 COVID-19 백신 접종 후 체액 반응의 발달을 확인하는 것입니다. {{ 방법: }} 시포니모드를 복용한 13개 pwSPMS와 11개 HC에서 코로나19 백신 접종 후 SARS-CoV2 항체 검사를 수행했습니다. {{ 결과: }} 시포니모드를 복용하는 pwSPMS는 건강한 대조군에 비해 SARS-CoV2 항체 역가가 유의하게 낮았습니다(19.4(0-250) 대 250(250), p>0.001). 시포니모드에 대한 2개(15.4%) pwSPMS는 SARS-CoV2-2 항체의 역가를 측정할 수 없었지만 모든 HC는 역가가 양성이었습니다. {{ 결론: }} 이 연구의 결과는 작은 표본 크기로 인해 제한되지만 결과는 siponimod의 pwSPMS에서 COVID-19 예방 접종 후 SARS-CoV-2 IgG 역가가 일관되게 낮음을 보여주었습니다. {{ 키워드: }} 코로나19; SARS-CoV-2 IgG 항체; 이차 진행성 다발성 경화증; 시포니모드; 백신.